Thymosin Alpha-1 Dosage Guide
Evidence-based protocols for the clinically proven immune modulator — pharmaceutical dosing from Zadaxin trials, immune modulation mechanisms, long-term therapy, stacking, and safety data from 35+ countries.
In This Guide
A leading innovator in research chemicals.
|Exclusive OfferUse our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.
Shop NowFor research purposes only. PeptideWiki may earn a commission at no extra cost to you.
Thymosin Alpha-1
For research purposes only. PeptideWiki may earn a commission at no extra cost to you.
What Is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1, thymalfasin) is a 28-amino-acid peptide originally isolated from thymic tissue (Thymosin Fraction 5) by Allan Goldstein and colleagues at George Washington University in the 1970s. It is one of the few peptides with genuine pharmaceutical approval — marketed as Zadaxin in over 35 countries for the treatment of chronic hepatitis B and as an immune adjuvant.
What distinguishes Thymosin Alpha-1 from most research peptides is the depth of its clinical evidence. It has been studied in Phase III clinical trials involving over 4,400 patients, published in hundreds of peer-reviewed papers, and used pharmaceutically for decades across Asia, Europe, and South America. This level of evidence far exceeds that of virtually any other peptide in the research community.
Tα1 functions as a true immune modulator — not simply an immune stimulant. It enhances T-cell maturation and differentiation (CD4+, CD8+, and NK cells), upregulates Toll-like receptor (TLR) expression on dendritic cells, promotes Th1 immune responses, and modulates key cytokines including IL-2, IFN-alpha, and IFN-gamma. Critically, it helps normalize both underactive and overactive immune responses, making it relevant to immunodeficiency, chronic infections, and potentially autoimmune conditions.
Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.
Key Characteristics:
- Pharmaceutical-grade evidence — Phase III clinical trials, 4,400+ patients studied, approved in 35+ countries as Zadaxin (thymalfasin)
- 28-amino-acid peptide — originally isolated from Thymosin Fraction 5 (bovine thymus) by Allan Goldstein at George Washington University
- True immune modulator — enhances underactive immune responses while helping regulate overactive ones — not a simple immune stimulant
- Mechanism of action — T-cell maturation (CD4+, CD8+, NK cells), TLR upregulation on dendritic cells, Th1 promotion, IL-2/IFN-alpha/IFN-gamma modulation
- Half-life ~2 hours — short plasma half-life, but immunomodulatory effects persist because Tα1 programs long-lasting immune cell changes
- Standard dose: 1.6 mg SubQ, 2x per week — established through Zadaxin Phase III trials; daily dosing (1.6 mg) used for acute immune support
For a complete overview of its mechanism and research, see our full Thymosin Alpha-1 profile. New to peptides? Start with the Beginner's Guide to Peptides.
How Thymosin Alpha-1 Dosage Is Determined
Thymosin Alpha-1 dosing is uniquely well-supported by clinical evidence. Unlike most research peptides, where dosing is extrapolated from animal studies and community anecdote, Tα1 dosing comes directly from randomized controlled trials and decades of pharmaceutical use. The standard 1.6 mg twice-weekly dose was not derived from community experimentation — it was established through formal clinical development.
Phase III Clinical Trials (Zadaxin)
The cornerstone of Tα1 dosing evidence comes from the Zadaxin clinical development program. Multiple Phase III randomized controlled trials studied 1.6 mg administered subcutaneously twice weekly in patients with chronic hepatitis B. These trials, conducted across multiple countries and involving thousands of patients, established both the efficacy and the safety of this dose over 6–12 months of continuous therapy. The 1.6 mg dose was selected based on earlier Phase I/II dose-finding studies that evaluated a range from 0.5 mg to 6.4 mg.
Dose-Response Characteristics
Phase I/II studies established that 1.6 mg produces optimal immune modulation with minimal side effects. Higher doses (3.2 mg and 6.4 mg) were studied and found to be safe but did not consistently produce superior immunological outcomes. This is consistent with Tα1's mechanism of action — it programs immune cell differentiation and maturation, processes that have a natural ceiling. More peptide does not necessarily translate to more immune programming once optimal receptor engagement is achieved.
Frequency Rationale: Why Twice Weekly?
Despite a plasma half-life of only ~2 hours, Tα1 is effective at twice-weekly dosing because its immunomodulatory effects are not dependent on continuous plasma presence. Each injection initiates immune cell maturation, TLR upregulation, and cytokine modulation that persists for days. The twice-weekly schedule provides consistent immunological stimulation while being practical for long-term patient compliance — a critical factor in 6–12 month therapy protocols.
Acute vs. Maintenance Dosing
Some clinical protocols and research settings use daily dosing (1.6 mg per day) for acute immune challenges — such as active infections, peri-operative immune support, or intensive cancer immunotherapy adjuvant protocols. Daily dosing is typically used for 2–4 weeks before transitioning to the standard twice-weekly maintenance regimen. This approach front-loads immune activation before settling into a sustainable long-term schedule.
Standard Thymosin Alpha-1 Dosage Ranges
Thymosin Alpha-1 is administered by subcutaneous injection. Unlike growth hormone secretagogues, it does not need to be injected fasted — its immune-modulating mechanism is not affected by food intake. The standard dose is 1.6 mg, which is the pharmaceutical dose established through Zadaxin clinical trials.
Dosage by Protocol Type
| Protocol | Dose per Injection | Frequency | Duration | Notes |
|---|---|---|---|---|
| Standard (Zadaxin) | 1.6 mg | 2x per week | 6–12 months | Pharmaceutical protocol; used for hepatitis B and general immune modulation |
| Acute / Intensive | 1.6 mg | Daily | 2–4 weeks | For active infections, peri-operative support, or front-loading before maintenance |
| Maintenance | 1.6 mg | 2x per week | Ongoing | Long-term immune support; can be continued indefinitely under medical supervision |
| Low-Dose Exploratory | 0.5–1.0 mg | 2–3x per week | 4–12 weeks | Conservative starting point; studied in Phase I trials but less common in practice |
Research-Documented Dose Ranges
| Dose | Context | Evidence Level |
|---|---|---|
| 0.5–1.0 mg | Phase I dose-finding; subtherapeutic in most contexts | Phase I clinical data |
| 1.6 mg (standard) | Zadaxin approved dose; hepatitis B, immune modulation, adjuvant therapy | Phase III RCTs (4,400+ patients) |
| 3.2 mg | Studied in some cancer immunotherapy and HIV protocols | Phase I/II clinical data |
| 6.4 mg | Highest studied dose; not standard practice | Phase I safety data |
Injection Timing
- No fasting required: Tα1 can be injected at any time of day regardless of meals
- Consistent schedule: For twice-weekly dosing, choose two days spaced 3–4 days apart (e.g., Monday/Thursday or Tuesday/Friday)
- Subcutaneous injection sites: Abdomen, thigh, or upper arm — rotate injection sites to minimize local reactions
- Storage: Reconstituted Tα1 should be refrigerated (2–8°C) and used within 28–30 days
Immune Peptide Comparison
Several peptides are used in research settings for immune-related applications. This comparison highlights how Thymosin Alpha-1 differs from other peptides commonly discussed in the context of immune support, healing, and recovery.
| Parameter | Thymosin Alpha-1 | TB-500 | BPC-157 | Epitalon |
|---|---|---|---|---|
| Primary Function | Immune modulation | Tissue repair / healing | Tissue repair / GI healing | Telomere / pineal function |
| Mechanism | T-cell maturation, TLR, cytokines | Actin sequestration, cell migration | VEGF, NO, growth factors | Telomerase activation, melatonin |
| Clinical Evidence | Phase III RCTs (strongest) | Preclinical / animal | Preclinical / animal | Limited human studies |
| Pharmaceutical Approval | Yes (35+ countries) | No | No | No |
| Typical Dose | 1.6 mg 2x/week | 2–5 mg 2x/week | 250–500 mcg 1–2x/day | 10 mg daily (10-day cycles) |
| Treatment Duration | Months to years | 4–12 weeks | 4–12 weeks | 10-day cycles, repeated |
| Side Effect Profile | Extremely well-tolerated | Minimal | Minimal | Minimal |
| Stacks Well With Tα1? | — | Yes (complementary) | Yes (complementary) | Yes (complementary) |
Calculate Your Thymosin Alpha-1 Dose
Thymosin Alpha-1 is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 10 mg vials in the research peptide market. The pharmaceutical Zadaxin product comes in pre-filled 1.6 mg doses, but research-grade Tα1 requires reconstitution. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe.
Worked Example:
- Vial size: 5 mg (5,000 mcg) of Thymosin Alpha-1
- Bacteriostatic water added: 1 mL
- Concentration: 5,000 mcg ÷ 1 mL = 5,000 mcg per mL (5 mg/mL)
- Target dose: 1,600 mcg (1.6 mg)
- Volume to draw: 1,600 ÷ 5,000 = 0.32 mL = 32 units on an insulin syringe
Quick Reference — 5 mg Vial
| Bac Water Added | Concentration | 1.6 mg Dose | Doses per Vial |
|---|---|---|---|
| 0.5 mL | 10,000 mcg/mL (10 mg/mL) | 16 units (0.16 mL) | ~3 doses |
| 1 mL | 5,000 mcg/mL (5 mg/mL) | 32 units (0.32 mL) | ~3 doses |
| 2 mL | 2,500 mcg/mL (2.5 mg/mL) | 64 units (0.64 mL) | ~3 doses |
Quick Reference — 10 mg Vial
| Bac Water Added | Concentration | 1.6 mg Dose | Doses per Vial |
|---|---|---|---|
| 1 mL | 10,000 mcg/mL (10 mg/mL) | 16 units (0.16 mL) | ~6 doses |
| 2 mL | 5,000 mcg/mL (5 mg/mL) | 32 units (0.32 mL) | ~6 doses |
| 3 mL | 3,333 mcg/mL (3.33 mg/mL) | 48 units (0.48 mL) | ~6 doses |
Skip the Math — Use Our
Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.
Thymosin Alpha-1 Dosage by Goal
Thymosin Alpha-1's broad immune-modulating mechanism makes it applicable to multiple clinical and research goals. The dosing protocol varies primarily in frequency and duration rather than dose size — the 1.6 mg per injection dose remains constant across most applications.
Chronic Hepatitis B Treatment
The primary approved indication for Zadaxin. Tα1 enhances the immune system's ability to clear hepatitis B virus by promoting T-cell maturation and Th1 immune responses. Clinical trials demonstrated significant improvements in viral load reduction and HBeAg seroconversion rates compared to placebo.
- Dose: 1.6 mg per injection (SubQ)
- Frequency: 2x per week (e.g., Monday/Thursday)
- Duration: 6–12 months (standard course)
- Monitoring: Regular viral load and liver function tests
General Immune Support & Optimization
For individuals seeking to optimize immune function — frequent illness, suboptimal immune markers, post-illness recovery, or age-related immune decline (immunosenescence). Tα1 addresses immune function at the fundamental level of T-cell maturation and innate immune receptor expression.
- Dose: 1.6 mg per injection (SubQ)
- Frequency: 2x per week
- Duration: 3–6 months initial course; can continue as maintenance
- Evaluation: Assess immune function markers and clinical response at 8–12 weeks
Acute Immune Challenge (Infection, Post-Surgical)
For short-term intensive immune support during active infections, peri-operative periods, or acute immune compromise. Daily dosing front-loads immune activation before transitioning to maintenance frequency. Research has explored this approach in sepsis, ARDS, and post-surgical recovery contexts.
- Dose: 1.6 mg per injection (SubQ)
- Frequency: Daily for 2–4 weeks
- Transition: After acute phase, step down to 1.6 mg 2x/week maintenance
- Note: Should be used under medical supervision in acute illness contexts
Cancer Immunotherapy Adjuvant
Research has explored Tα1 as an adjuvant to cancer immunotherapy and chemotherapy. The rationale is that Tα1 may help restore immune function that is suppressed by cancer and its treatments, potentially improving response to immunotherapy agents. This is an active area of clinical investigation.
- Dose: 1.6–3.2 mg per injection (SubQ)
- Frequency: 2x per week to daily (varies by protocol)
- Duration: Throughout treatment course
- Critical: Must be coordinated with the treating oncologist
Vaccine Enhancement
Tα1 has been studied as a vaccine adjuvant to improve antibody response rates in immunocompromised populations (elderly, HIV-positive, dialysis patients). By enhancing dendritic cell function and T-cell maturation, it may improve the immune system's response to vaccination.
- Dose: 1.6 mg per injection (SubQ)
- Frequency: 2x per week, starting 2–4 weeks before vaccination and continuing 2–4 weeks after
- Duration: 4–8 weeks total
- Note: Research context; consult your physician regarding any vaccine protocol modifications
Cycling & Long-Term Use
Thymosin Alpha-1 has a fundamentally different cycling profile than most research peptides. Unlike growth hormone secretagogues (which desensitize receptors and require mandatory on/off cycling), Tα1 works through immune cell programming — maturation, differentiation, and receptor upregulation — processes that do not exhibit the same receptor desensitization. This allows for much longer continuous use.
Protocol Options
| Protocol | Duration | Frequency | Notes |
|---|---|---|---|
| Short Course | 4–8 weeks | 1.6 mg 2x/week | Minimum practical duration; suitable for acute immune support or vaccine enhancement |
| Standard Course | 6–12 months | 1.6 mg 2x/week | Pharmaceutical Zadaxin protocol; used for hepatitis B and chronic immune modulation |
| Front-Loaded Course | 2–4 weeks daily, then 3–6 months 2x/week | 1.6 mg daily → 1.6 mg 2x/week | Intensive start followed by maintenance; used for acute infections or post-surgical recovery |
| Indefinite Maintenance | Ongoing | 1.6 mg 2x/week | Some practitioners continue Tα1 indefinitely for ongoing immune optimization; safety data supports long-term use |
Why No Mandatory Off-Cycles?
Thymosin Alpha-1 does not desensitize its target pathways the way GHRPs desensitize the GHS-R1a receptor. Tα1 works by programming immune cells — once a T-cell is matured, a TLR is upregulated, or a cytokine profile is shifted, the effect persists independently of continued Tα1 presence. There is no receptor downregulation that requires an off-period to reverse. Clinical studies running 6–12 months of continuous therapy confirmed sustained immunological benefits without evidence of tolerance or diminishing returns.
Optional Cycling for Research Use
While not pharmacologically necessary, some research peptide users choose to cycle Tα1 for practical reasons (cost management, periodic reassessment, or general preference for periodic breaks). A reasonable optional cycle would be:
- 3 months on, 1 month off: Allows periodic reassessment of immune status
- 6 months on, 2 months off: Mirrors the clinical trial duration with a rest period
- Continuous: Supported by clinical evidence; no pharmacological reason to cycle off
Thymosin Alpha-1 Stacking Protocols
Thymosin Alpha-1 stacks well with many peptides because its immune-modulating mechanism is distinct from hormonal, tissue repair, and neuroprotective pathways. It does not compete for the same receptors as growth hormone secretagogues, healing peptides, or longevity-focused compounds, making it highly compatible in multi-peptide protocols.
Thymosin Alpha-1 + BPC-157 — Immune Support + Tissue Repair
Combines Tα1's systemic immune modulation with BPC-157's targeted tissue repair and anti-inflammatory effects. Ideal for post-injury or post-surgical recovery where both immune function and tissue healing are important. BPC-157 promotes angiogenesis and growth factor upregulation at injury sites while Tα1 ensures the immune system supports rather than hinders the healing process.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| Thymosin Alpha-1 | 1.6 mg SubQ | 2x per week | Systemic immune modulation, T-cell support, TLR upregulation |
| BPC-157 | 250–500 mcg SubQ | 1–2x daily | Localized tissue repair, angiogenesis, growth factor upregulation |
Thymosin Alpha-1 + TB-500 — Immune Modulation + Systemic Healing
Pairs Tα1's immune programming with TB-500's systemic tissue repair and anti-inflammatory properties. Despite sharing the “thymosin” name, these peptides have entirely different mechanisms and are highly complementary. Tα1 optimizes immune function while TB-500 promotes cell migration, wound healing, and reduces inflammation throughout the body.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| Thymosin Alpha-1 | 1.6 mg SubQ | 2x per week | Immune modulation, T-cell maturation, cytokine balance |
| TB-500 | 2–5 mg SubQ | 2x per week (loading), then 1x/week (maintenance) | Systemic tissue repair, anti-inflammation, cell migration |
Thymosin Alpha-1 + Epitalon — Immune Support + Longevity
A longevity-focused combination. Tα1 addresses age-related immune decline (immunosenescence) by restoring T-cell function and innate immune responsiveness. Epitalon supports telomere maintenance through telomerase activation and pineal gland function. Together, they address two key dimensions of aging — immune erosion and cellular senescence.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| Thymosin Alpha-1 | 1.6 mg SubQ | 2x per week (continuous) | Immune modulation, counter immunosenescence, T-cell restoration |
| Epitalon | 10 mg SubQ | Daily for 10 days, repeat every 3–6 months | Telomerase activation, pineal function, anti-aging |
Thymosin Alpha-1 + BPC-157 + TB-500 — Comprehensive Recovery Stack
A three-peptide combination for comprehensive recovery — immune optimization (Tα1), systemic healing (TB-500), and targeted tissue repair (BPC-157). This stack addresses recovery from multiple angles and is commonly discussed in the context of post-surgical recovery, major injury rehabilitation, and chronic illness recovery.
Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.
Safety, Side Effects & Contraindications
Known Side Effects
Rare and generally mild:
- Injection site reactions — mild redness, swelling, or soreness at the injection site; the most commonly reported adverse event in clinical trials
- Mild flu-like symptoms — low-grade fever, fatigue, or myalgia in the first 1–2 weeks; considered a sign of immune activation rather than toxicity, and typically resolves spontaneously
- Transient fatigue — reported rarely; may relate to immune system recalibration during the initial treatment phase
Not reported in clinical use at standard doses:
- No hormonal disruption — Tα1 does not affect cortisol, prolactin, testosterone, or growth hormone levels
- No hepatotoxicity — used specifically for liver disease (hepatitis B) without liver toxicity
- No nephrotoxicity — no kidney function impairment reported in clinical use
- No significant drug interactions — has been safely combined with interferon, antivirals, and chemotherapy in clinical studies
Contraindications
- Known hypersensitivity — allergy to thymalfasin or any component of the formulation is a contraindication
- Organ transplant recipients — Tα1's immune-enhancing effects could potentially interfere with immunosuppressive therapy required to prevent organ rejection. Use only under transplant physician guidance.
- Active autoimmune disease (use with caution) — while Tα1 has bidirectional immune-modulating properties, individuals with active autoimmune flares should consult their physician before use. Tα1 is being researched in autoimmune contexts, but clinical data is not yet definitive.
- Pregnancy and breastfeeding — insufficient safety data during pregnancy or nursing. Avoid use until adequate reproductive toxicity data is available.
- Concurrent immunosuppressive therapy — Tα1 may counteract immunosuppressive medications. Always consult the prescribing physician before combining with immunosuppressants.
Monitoring Recommendations
- Baseline and periodic blood work: Complete blood count (CBC) with differential, comprehensive metabolic panel, and immune markers (CD4/CD8 ratio, NK cell count) if available
- For hepatitis B: HBV viral load, HBeAg/anti-HBe status, liver function tests at regular intervals
- Clinical assessment: Track frequency of infections, energy levels, and overall well-being as subjective markers of immune function improvement
- For cancer adjuvant use: Regular oncology monitoring as directed by the treating physician
Common Thymosin Alpha-1 Dosing Mistakes
Avoid these common errors to get the most out of your Thymosin Alpha-1 protocol:
Frequently Asked Questions
Key Takeaways
- Thymosin Alpha-1 is one of the best-evidenced peptides available — Phase III clinical trials, 4,400+ patients studied, approved as Zadaxin in 35+ countries
- Standard dose: 1.6 mg SubQ, 2x per week — this is the pharmaceutical dose established through formal clinical development and used worldwide
- True immune modulator, not just a stimulant — enhances underactive immune responses while helping regulate overactive ones through T-cell maturation, TLR upregulation, and cytokine modulation
- No mandatory cycling required — unlike GHRPs, Tα1 does not cause receptor desensitization. Clinical protocols run continuously for 6–12 months
- Extremely well-tolerated — the most extensive safety data of any research peptide. Rare injection site reactions and occasional mild flu-like symptoms are the only commonly reported side effects
- Acute protocol: 1.6 mg daily for 2–4 weeks — used for active infections, peri-operative support, or front-loading before maintenance dosing
- Stacks well with healing and longevity peptides — BPC-157, TB-500, and Epitalon are all complementary through distinct mechanisms
- Not FDA-approved in the US — approved in 35+ countries as Zadaxin. Available as a research peptide in the United States with orphan drug designation
- Key research areas: chronic hepatitis B/C, cancer immunotherapy adjuvant, vaccine enhancement, HIV support, sepsis/ARDS, post-surgical recovery, and immunosenescence
- Do not confuse with TB-500 (Thymosin Beta-4) — different peptides with different structures, mechanisms, and dosing protocols despite the shared thymosin name
This article is for educational and informational purposes only. See our Disclaimer.
References
- Goldstein AL, et al. “Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide.” Proc Natl Acad Sci USA. 1977;74(2):725-729. PubMed
- Garaci E, et al. “Thymosin alpha 1: from bench to bedside.” Ann N Y Acad Sci. 2007;1112:225-234. PubMed
- Tuthill C, et al. “Thymalfasin: biological properties and clinical applications.” Int Immunopharmacol. 2010;10(10):1174-1178.
- Andreone P, et al. “A randomized controlled trial of thymalfasin and PEGylated interferon alpha-2a for hepatitis B e antigen-positive chronic hepatitis B.” Hepatology. 2011;54(2):472-480.
- Chien RN, et al. “Long-term efficacy of thymalfasin for treatment of HBeAg positive hepatitis B.” Hepatology. 2006;44(S1):S233.
- Romani L, et al. “Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance.” Blood. 2006;108(7):2265-2274. PubMed
- Serafino A, et al. “Thymosin alpha 1 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages.” J Innate Immun. 2012;4(1):87-96. PubMed
- Pica F, et al. “Thymosin alpha 1 modulates the TLR9-mediated immunostimulatory properties of CpG-oligodeoxynucleotides in the mouse.” Int Immunopharmacol. 2014;20(1):205-210.
- Matteucci C, et al. “Thymosin alpha 1 and HIV-1: recent advances and future perspectives.” Future Microbiol. 2017;12:141-155. PubMed
- Goldstein AL, Goldstein AL. “From lab to bedside: emerging clinical applications of thymosin alpha 1.” Expert Opin Biol Ther. 2009;9(5):593-608. PubMed
- Li J, et al. “Thymosin alpha 1 as adjunctive therapy for hepatocellular carcinoma: a systematic review and meta-analysis.” Onco Targets Ther. 2016;9:3537-3546.
- Maio M, et al. “Thymosin alpha 1 in the management of cancer patients receiving chemotherapy.” Expert Opin Biol Ther. 2010;10(10):1451-1458.
Next Steps
Continue your research with these resources.
BPC-157 Dosage Guide
Learn dosing protocols for BPC-157 — the versatile tissue repair peptide that stacks perfectly with Thymosin Alpha-1.
Read GuideDosage Calculator
Calculate your exact Thymosin Alpha-1 dose based on vial size and reconstitution volume.
Open CalculatorPeptide Directory
Browse all peptides with research summaries and dosing data.
View Directory